Safety of [(177)Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity

PURPOSE: The radiolabeled gastrin-releasing peptide receptor (GRPR)-targeting antagonist NeoB is a promising radioligand for imaging and therapy of GRPR-expressing malignancies. In the current study, we aimed to discover the target organs of toxicity and the radiotoxic effects to these organs, when...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruigrok, Eline A. M., Verhoeven, Marjolein, Konijnenberg, Mark W., de Blois, Erik, de Ridder, Corrina M. A., Stuurman, Debra C., Bertarione, Luisa, Rolfo, Katia, de Jong, Marion, Dalm, Simone U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605926/
https://www.ncbi.nlm.nih.gov/pubmed/35951084
http://dx.doi.org/10.1007/s00259-022-05926-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605926/
https://www.ncbi.nlm.nih.gov/pubmed/35951084
http://dx.doi.org/10.1007/s00259-022-05926-2

Ejemplares similares